HDAC-dependent ventricular remodeling

Trends in Cardiovascular Medicine

Volumn 23, Issue 6, 2013, Pages 229-235

  Xie, Min ^a   Hill, Joseph A ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; BUTYRIC ACID; CYCLOPEPTIDE; DEPSIPEPTIDE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; ROMIDEPSIN; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

ACETYLATION; ANEMIA; AUTOPHAGY; BONE MARROW SUPPRESSION; CORONARY ARTERY DISEASE; ENZYME INHIBITION; HEART FAILURE; HEART HYPERTROPHY; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HEART VENTRICLE PRESSURE; HEART VENTRICLE REMODELING; HUMAN; ISCHEMIC HEART DISEASE; LEUKOPENIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; REPERFUSION INJURY; REVIEW; STRESS;

ACETYLATION; ANIMALS; CARDIOVASCULAR AGENTS; HEART FAILURE; HEART VENTRICLES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; VENTRICULAR REMODELING;

EID: 84880036835     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2012.12.006     Document Type: Review

References (48)

1. Alcendor R.R., Gao S., Zhai P., Zablocki D., Holle E., Yu X., et al. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circulation Research 2007, 100:1512-1521.
2. Alcendor R.R., Kirshenbaum L.A., Imai S., Vatner S.F., Sadoshima J. Silent information regulator 2alpha, a longevity factor and class III histone deacetylase, is an essential endogenous apoptosis inhibitor in cardiac myocytes. Circulation Research 2004, 95:971-980.
3. Antos C.L., McKinsey T.A., Dreitz M., Hollingsworth L.M., Zhang C.L., Schreiber K., et al. Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. Journal of Biological Chemistry 2003, 278:28930-28937.
4. Backs J., Song K., Bezprozvannaya S., Chang S., Olson E.N. CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. Journal of Clinical Investigation 2006, 116:1853-1864.
5. Barter M.J., Pybus L., Litherland G.J., Rowan A.D., Clark I.M., Edwards D.R., et al. HDAC-mediated control of ERK- and PI3K-dependent TGF-beta-induced extracellular matrix-regulating genes. Matrix Biology 2010, 29:602-612.
6. Bradner J.E., West N., Grachan M.L., Greenberg E.F., Haggarty S.J., Warnow T., et al. Chemical phylogenetics of histone deacetylases. Nature Chemical Biology 2010, 6:238-243.
7. Bush E., Fielitz J., Melvin L., Martinez-Arnold M., McKinsey T.A., Plichta R., et al. A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:2870-2875.
8. Cao D.J., Wang Z.V., Battiprolu P.K., Jiang N., Morales C.R., Kong Y., et al. Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:4123-4128.
9. Chang S., McKinsey T.A., Zhang C.L., Richardson J.A., Hill J.A., Olson E.N. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Molecular and Cellular Biology 2004, 24:8467-8476.
10. Dooley R., Harvey B.J., Thomas W. The regulation of cell growth and survival by aldosterone. Frontiers in Bioscience: A Journal and Virtual Library 2011, 16:440-457.
11. Goldberg L.R. Heart failure. Annals of Internal Medicine 2010, 152. [ITC61-15; quiz ITC616].
12. Granger A., Abdullah I., Huebner F., Stout A., Wang T., Huebner T., et al. Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB Journal 2008, 22:3549-3560.
13. Gregoretti IV, Lee YM, Goodson HV Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis. Journal of Molecular Biology 2004, 338:17-31.
14. Haberland M., Mokalled M.H., Montgomery R.L., Olson E.N. Epigenetic control of skull morphogenesis by histone deacetylase 8. Genes & Development 2009, 23:1625-1630.
15. Han A., He J., Wu Y., Liu J.O., Chen L. Mechanism of recruitment of class II histone deacetylases by myocyte enhancer factor-2. Journal of Molecular Biology 2005, 345:91-102.
16. Han A., Pan F., Stroud J.C., Youn H.D., Liu J.O., Chen L. Sequence-specific recruitment of transcriptional co-repressor Cabin1 by myocyte enhancer factor-2. Nature 2003, 422:730-734.
17. Heidenreich P.A., Trogdon J.G., Khavjou O.A., Butler J., Dracup K., Ezekowitz M.D., et al. Forecasting the future of cardiovascular disease in the United States: A policy statement from the American Heart Association. Circulation 2011, 123:933-944.
18. Iyer A., Fenning A., Lim J., Le G.T., Reid R.C., Halili M.A., et al. Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. British Journal of Pharmacology 2010, 159:1408-1417.
19. Kee H.J., Kook H. Kruppel-like factor 4 mediates histone deacetylase inhibitor-induced prevention of cardiac hypertrophy. Journal of Molecular and Cellular Cardiology 2009, 47:770-780.
20. Kee H.J., Sohn I.S., Nam K.I., Park J.E., Qian Y.R., Yin Z., et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 2006, 113:51-59.
21. Kehat I., Molkentin J.D. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation 2010, 122:2727-2735.
22. Kong Y., Tannous P., Lu G., Berenji K., Rothermel B.A., Olson E.N., et al. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 2006, 113:2579-2588.
23. Kook H., Lepore J.J., Gitler A.D., Lu M.M., Wing-Man Yung W., Mackay J., et al. Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. Journal of Clinical Investigation 2003, 112:863-871.
24. Lee T.M., Lin M.S., Chang N.C. Inhibition of histone deacetylase on ventricular remodeling in infarcted rats. American Journal of Physiology-Heart and Circulatory Physiology 2007, 293:H968-H977.
25. Liao X., Haldar S.M., Lu Y., Jeyaraj D., Paruchuri K., Nahori M., et al. Kruppel-like factor 4 regulates pressure-induced cardiac hypertrophy. Journal of Molecular and Cellular Cardiology 2010, 49:334-338.
26. Liu F., Levin M.D., Petrenko N.B., Lu M.M., Wang T., Yuan L.J., et al. Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin. Journal of Molecular and Cellular Cardiology 2008, 45:715-723.
27. McKinsey T.A. Therapeutic potential for HDAC inhibitors in the heart. Annual Review of Pharmacology and Toxicology 2012, 52:303-319.
28. McKinsey T.A., Zhang C.L., Olson E.N. MEF2: A calcium-dependent regulator of cell division, differentiation and death. Trends in Biochemical Sciences 2002, 27:40-47.
29. Mizushima N. Autophagy: Process and function. Genes & Development 2007, 21:2861-2873.
30. Montgomery R.L., Davis C.A., Potthoff M.J., Haberland M., Fielitz J., Qi X., et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes & Development 2007, 21:1790-1802.
31. Munster PN, Rubin EH, Van Belle S, Friedman E., Patterson J.K., Van Dyck K., et al. A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2009, 15:7077-7084.
32. Nakai A., Yamaguchi O., Takeda T., Higuchi Y., Hikoso S., Taniike M., et al. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nature Medicine 2007, 13:619-624.
33. Piekarz R.L., Frye A.R., Wright J.J., Steinberg S.M., Liewehr D.J., Rosing D.R., et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2006, 12:3762-3773.
34. Piot C., Croisille P., Staat P., Thibault H., Rioufol G., Mewton N., et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. New England Journal of Medicine 2008, 359:473-481.
35. Rikiishi H. Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. Journal of Biomedicine & Biotechnology 2011, 2011:830260.
36. Rubinsztein D.C., Codogno P., Levine B. Autophagy modulation as a potential therapeutic target for diverse diseases. Nature Reviews. Drug Discovery 2012, 11:709-730.
37. Schwartz Longacre L., Kloner R.A., Arai A.E., Baines C.P., Bolli R., Braunwald E., et al. New horizons in cardioprotection: Recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop. Circulation 2011, 124:1172-1179.
38. Sundaresan N.R., Samant S.A., Pillai V.B., Rajamohan S.B., Gupta M.P. SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70. Molecular and Cellular Biology 2008, 28:6384-6401.
39. Trivedi C.M., Lu M.M., Wang Q., Epstein J.A. Transgenic overexpression of Hdac3 in the heart produces increased postnatal cardiac myocyte proliferation but does not induce hypertrophy. Journal of Biological Chemistry 2008, 283:26484-26489.
40. Vakhrusheva O., Smolka C., Gajawada P., Kostin S., Boettger T., Kubin T., et al. Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circulation Research 2008, 102:703-710.
41. Vega R.B., Harrison B.C., Meadows E., Roberts C.R., Papst P.J., Olson E.N., et al. Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Molecular and Cellular Biology 2004, 24:8374-8385.
42. Xie M., Morales C.R., Lavandero S., Hill J.A. Tuning flux: Autophagy as a target of heart disease therapy. Current Opinion in Cardiology 2011, 26:216-222.
43. Yang X.J., Seto E. Lysine acetylation: Codified crosstalk with other posttranslational modifications. Molecular Cell 2008, 31:449-461.
44. Yoshikawa M., Hishikawa K., Idei M., Fujita T. Trichostatin a prevents TGF-beta1-induced apoptosis by inhibiting ERK activation in human renal tubular epithelial cells. European Journal of Pharmacology 2010, 642:28-36.
45. Zhang C.L., McKinsey T.A., Chang S., Antos C.L., Hill J.A., Olson E.N. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002, 110:479-488.
46. Zhang L., Chen B., Zhao Y., Dubielecka P.M., Wei L., Qin G.J., et al. Inhibition of histone deacetylase-induced myocardial repair is mediated by c-kit in infarcted hearts. Journal of Biological Chemistry 2012, 287:39338-39348.
47. Zhao T.C., Cheng G., Zhang L.X., Tseng Y.T., Padbury J.F. Inhibition of histone deacetylases triggers pharmacologic preconditioning effects against myocardial ischemic injury. Cardiovascular Research 2007, 76:473-481.
48. Zhu H., Tannous P., Johnstone J.L., Kong Y., Shelton J.M., Richardson J.A., et al. Cardiac autophagy is a maladaptive response to hemodynamic stress. Journal of Clinical Investigation 2007, 117:1782-1793.